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Abstract
Background: Routine immunization, one of the most effective public health interventions, has effectively reduced
death and morbidity due to a variety of infectious diseases. However, allergic reactions to vaccines occur very rarely
and can be life threatening. Given the large numbers of vaccines administered worldwide, there is a need for an
international consensus regarding the evaluation and management of allergic reactions to vaccines.
Methods: Following a review of the literature, and with the active participation of representatives from the
World Allergy Organization (WAO), the European Academy of Allergy and Clinical Immunology (EAACI), the
American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy,
Asthma, and Immunology (ACAAI), the final committee was formed with the purpose of having members who
represented a wide-range of countries, had previously worked on vaccine safety, and included both allergist/
immunologists as well as vaccinologists.
Results: Consensus was reached on a variety of topics, including: definition of immediate allergic reactions,
including anaphylaxis, approaches to distinguish association from causality, approaches to patients with a
history of an allergic reaction to a previous vaccine, and approaches to patients with a history of an allergic
reaction to components of vaccines.
Conclusions: This document provides comprehensive and internationally accepted guidelines and access to
on-line documents to help practitioners around the world identify allergic reactions following immunization.
It also provides a framework for the evaluation and further management of patients who present either following an
allergic reaction to a vaccine or with a history of allergy to a component of vaccines.
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Introduction
Routine immunization, one of the most effective public
health interventions, has effectively reduced death and
morbidity due to a variety of infectious diseases [1, 2].
Very rarely, allergic reactions to vaccines occur, and
can be life threatening [3–6]. Estimates of allergic reac-
tions to vaccines including immediate hypersensitivity
reactions, range from 1 in 50,000 to 1 in 1,000,000
doses [7–9]. The most concerning of these, anaphylaxis,
has been estimated to occur at a rate of approximately
one per 100,000 to one per 1,000,000 doses for most
commonly administered vaccines [8, 10, 11] (B)1. The
true rate of allergic reactions is unknown because most
reactions are not reported.
Allergic reactions need to be distinguished from clinical
manifestations that occur coincidental to vaccination (e.g.
becoming anxious), vasovagal responses, local injection-
site reactions (either immediate or delayed), and the
oculorespiratory syndrome (ORS). Allergic reactions are
generally immediate and IgE-mediated. Symptoms vary
from relatively minor cutaneous signs and symptoms
(erythema and itching) to multisystem effects (anaphyl-
axis) that can include the cutaneous, respiratory,
gastrointestinal, and/or cardiovascular systems. Allergic
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reactions can be due to allergy to vaccine antigens (por-
tions of organisms or toxoids), residual media used to
grow organisms, stabilizers, preservatives, or other
excipients [6] (B). Given the increasing prevalence of
allergic disease throughout the world [12–15], it is not
surprising that there are increasing concerns about pos-
sible allergic reactions following vaccines and concerns
about vaccine components.
Patients may have clinical complaints that occur im-
mediately subsequent to administration of a vaccine
that may or may not be compatible with an allergic re-
action, but nonetheless have significant impact on the
patient’s perception of vaccines and their willingness to
undergo further vaccination. In addition, patients may
have complaints that have a delayed onset relative to
having received a vaccine that raise concerns about
delayed allergic or other immunologic reactions to vac-
cine components.
A variety of very useful documents in the literature
have addressed many of these concerns [3–6], but none
have addressed all of these issues or have presented an
international consensus. For this reason, the World Al-
lergy Organization (WAO) initiated an effort to publish
this International CONsensus (ICON) on allergic reac-
tions to vaccines. The intent of this document is to iden-
tify themes that commonly occur in a large variety of
settings and to provide a comprehensive reference for a
systematic approach to the problems related to allergic
reactions to vaccines.
Following the above introduction (Part I), this docu-
ment is organized to first describe our methodology,
process, and to provide definitions (Part II). In subse-
quent sections, we review allergic reactions to specific
vaccines (Part III) and then allergic reactions to compo-
nents of vaccines (Part IV). Finally, we address the rec-
ommended approach to the patient with a history of an
allergic reaction to vaccines (Part V) and to the patient
with a history of an allergic reaction to an exogenous
substance (e.g. food, drug, or latex) that may be found in
a vaccine or its packaging (Part VI). In closing, we
address unmet needs and offer suggestions for future
research (Part VII). Since some specific vaccines are




Under the auspices of WAO, a working committee was
formed, consisting of Drs. Rosenwasser, Dreskin, and
Halsey. Following a review of the literature, and with the
active participation of representatives from the European
Academy of Allergy and Clinical Immunology (EAACI),
the American Academy of Allergy, Asthma, and Immun-
ology (AAAAI), the American College of Allergy, Asthma,
and Immunology (ACAAI), the final committee was
formed with the purpose of having members who repre-
sented a wide-range of countries, had previously worked
on vaccine safety, and included both allergist/immunolo-
gists as well as vaccinologists.
Process
Following email contact, a conference call was convened
during which participants agreed to write or to help
write specific parts of this ICON, relying heavily on pre-
viously published ICONs as well as a practice parameter
on adverse reactions to vaccines and other reviews of al-
lergic reactions to vaccines [3–6]. The first draft of a
complete document was then compiled by Drs. Dreskin
and Halsey and subsequently sent to all participants for
final editing. A second conference call was then held to
discuss differences in opinion. Then a final draft was
sent to participants for their review. This draft was then
sent to an independent committee (chosen on the basis
of participating in previous ICONs) and their com-
ments circulated back to the committee for decision
regarding further alteration. A final document was
then approved by the Board of Directors of the spon-
soring organizations.
Definitions
Immediate reactions that are not allergic (Immediate
non-allergic reactions)
Local, injection site reactions (swelling, redness, and/
or soreness) and constitutional symptoms, especially
fever, are common after the administration of many
vaccines and are not contraindications to subsequent
vaccination [16] (D).
Immediate allergic reactions
Immediate hypersensitivity or allergic reactions to vac-
cines are rare but potentially serious adverse events that
require investigation and understanding of the associ-
ated risks in order to properly counsel patients regarding
the risk versus benefit ratio for the administration of
future vaccines. In this document, “allergy” will be used
interchangeably with “immediate hypersensitivity” and
“IgE-mediated reaction” as descriptors to denote a pre-
sumed underlying IgE-mediated immune mechanism for
an adverse event. We use the term “immediate” to dis-
tinguish these allergic reactions from those that may be
mediated by antibodies other than IgE or by T cells
(commonly seen in immunologic reactions to drugs).
Limited immediate allergic reactions
Allergic reactions to vaccines may be mild and limited
in the scope of symptoms and involvement of organ
systems, or even localized to the site of vaccine adminis-
tration. Thus, typical signs of an allergic reaction may
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include bronchoconstriction, rhinoconjunctivitis, gastro-
intestinal symptoms, and/or characteristic skin lesions
such as generalized urticaria and/or angioedema [17],
occurring as a sole sign with an onset within minutes
and less than 4 h post-vaccination [4] (D).
Anaphylaxis
Definition of Anaphylaxis
Anaphylaxis is the most severe form of an IgE-mediated re-
action, encompassing a spectrum of symptoms and in-
volvement of several organ systems. For the majority of
instances, anaphylaxis occurs within minutes following an
exposure to an allergen. The International Consensus on
(ICON) Anaphylaxis published in 2014 reviewed defini-
tions proposed by WAO; the Joint Task Force on Practice
Parameters, representing the AAAAI, the ACAAI, and the
Joint Council of Allergy, Asthma, and Immunology
(JCAAI); and the EAACI. In this consensus docu-
ment, all organizations have agreed upon the concept
that anaphylaxis is a “serious, generalized or systemic,
allergic or hypersensitivity reaction that can be life-
threatening or fatal” [18] (D).
The National Institutes of Allergy and Infectious Dis-
eases (NIAID) / Food Allergy and Anaphylaxis Network
(FAAN) criteria developed in 2006 by an NIH meeting
of experts in the fields of allergy and immunology de-
fined anaphylaxis as one of three scenarios: 1) The acute
onset of an illness within minutes or hours with involve-
ment of: skin and/or mucosa (pruritus, flushing, hives,
angioedema), and either respiratory compromise (dys-
pnea, wheeze/bronchospasm, decreased peak expiratory
flow, stridor, hypoxemia) OR decreased blood pressure/
end organ dysfunction (collapse, syncope, incontinence)
2) Two or more of the following that occur rapidly after
exposure to a likely allergen for that patient: skin and/
or mucosa; respiratory compromise; decreased blood
pressure/end organ dysfunction; persistent GI symp-
toms (vomiting, crampy abdominal pain, diarrhea) 3)
The following within minutes or hours after exposure
of a known allergen for that patient: decreased blood
pressure [19] (D).
Alternative criteria include those developed by the
Brighton Collaboration Working Group for case defini-
tions [20] (D). These criteria are not intended to distin-
guish differing levels of severity of anaphylaxis, but
instead denote different levels of diagnostic certainty, as
the definition is used primarily for epidemiologic studies.
A Level 1 case definition has the highest level of diag-
nostic certainty, with progressively lower certainty for
levels 2 and 3, respectively. Because these levels do not
directly define severity, it is possible for a very severe
clinical event to be classified as a level 2 or 3, based on
the available information. Furthermore, appropriate rapid
treatment of an incipient immediate hypersensitivity
reaction with intramuscular epinephrine may modulate
the severity of the reaction [18] (D).
Although most episodes of anaphylaxis involve cuta-
neous symptoms of urticaria and/or angioedema, this
is not universally the case. Skin and/or mucosal signs
may be absent in 10–20 % of all episodes, and
hypotension in infants often remains unrecognized.
Unique aspects of anaphylaxis in infants, including be-
havioral changes and challenges regarding recognition
of cardiovascular signs has recently been reviewed
[21]. In general, underreporting of anaphylaxis is likely
common [22] (D).
Most episodes of anaphylaxis occur with a sudden on-
set and rapid progression [23] (D). Biphasic reactions are
also described, in which an initial clinical presentation
resolves with or without treatment, to be followed later
(up to 72 h) by a recurrence [24, 25] (D). Protracted ana-
phylaxis (lasting up to several days without resolution)
has also been described, but is uncommon and the lit-
erature consists only of case reports or small series [26]
(D). Protracted anaphylaxis has been reported following
administration of vaccines [11] (D).
It is therefore not possible to assign a strict time frame
(time from exposure to onset of symptoms) upon the
definition of anaphylaxis in relation to a potential trig-
gering event, such as an immunization. The AAAAI and
ACAAI Joint Task Force on Practice Parameters advised
considering events with onset within 4 h of vaccine ad-
ministration as possibly consistent with anaphylaxis [4]
(D). Guidelines from the EAACI note that symptoms
and signs of anaphylaxis usually occur within 2 h of ex-
posure to the allergen and this is even faster following
exposure to parenteral medications or insect stings
(venom) [27] (D). A review of a registry of anaphylactic
reactions in the UK found that the median time to re-
spiratory or cardiac arrest for reactions to venom (a par-
enteral exposure) was 15 min, with the longest interval
being 120 min [28] (D).
The differential diagnosis of, and the potential triggers
for, anaphylaxis must be considered whenever an epi-
sode appears to coincide with vaccine administration,
since assessing the likelihood of causality (i.e. the vaccine
causing anaphylaxis) is heavily dependent upon there be-
ing no alternative cause that can be implicated (Table 1)
[29] (D).
The WAO has suggested removing the term “anaphy-
lactoid” from use, and this is supported by the most re-
cent update of anaphylaxis published by the Joint Task
Force on Practice Parameters, representing the AAAAI,
the ACAAI, and the JCAAI [29] (D). Historically, this
term referred to the same syndrome as anaphylaxis
that was caused by immune mechanisms, but not in-
volving serum IgE specific for an allergen. Other non-
IgE-mediated immunologic mechanisms may cause
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anaphylaxis. For example, IgG-mediated and immune
complex-mediated anaphylaxis has been reported for
certain medications and biologic agents [30] (D), and
non-immune activation of mast cells and basophils
may occur [31]. However, it is now recognized that
because anaphylaxis is a syndrome, with specific clin-
ical features, and because the underlying immune
mechanisms cannot easily be ascertained at the time
of the event, it is essential to treat all episodes that
fall into this category the same. Non-IgE-mediated
events will not be discussed in this document except
as they may be considered in the differential diagnosis
for an adverse event (Table 1).
The CDC and FDA supported passive surveillance sys-
tem, Vaccine Adverse Event Reporting System (VAERS),
uses the term “serious” to include death, hospitalization
or prolongation of hospitalization, persistent or signifi-
cant disability/incapacity, or is life threatening. In this
document, we use “serious” throughout the document in
the same manner as clinicians use the term and not
precisely as defined by VAERS.
Differential diagnosis of anaphylaxis
There are a number of immediate adverse events follow-
ing immunization that could be misdiagnosed as ana-
phylaxis. For example, sudden events such as syncope
following immunization may be confused with anaphyl-
axis. Many of these adverse events occur more commonly
than vaccine related anaphylaxis and alternative diagnoses
should be considered when a case definition for anaphyl-
axis is not met.
Anaphylaxis (all causes) usually presents with charac-
teristic and predictable multi-system findings; less than
10 % of episodes present with sudden onset of hypotension
(manifest as collapse/unresponsiveness) without concomi-
tant respiratory manifestations and/or cutaneous signs
(erythema, urticaria or angioedema). When sudden
collapse or acute respiratory symptoms occur without
skin changes following immunization, anaphylaxis
should be considered.
Adverse events, other than anaphylaxis, that commonly
result in sudden collapse and unresponsiveness following
immunization include, in an infant, a Hypotonic Hypore-
sponsive Episode (HHE). HHE is characterized by the sud-
den onset of unresponsiveness, hypotonia and pallor, and
usually presents 1-to-6 h after immunization [32]. Cardio-
vascular compromise and specifically hypotension does
not occur in HHE. Vasovagal syncope can occur at all ages
and is now a frequently reported adverse event since ado-
lescents are at increased risk and adolescent vaccination is
widely promoted in some countries [33]. In vasovagal syn-
cope, hypotension is transient and associated with brady-
cardia rather than tachycardia as would occur typically in
anaphylaxis. Sudden unresponsiveness due to a febrile
seizure following immunization is frequently associated
with tonic-clonic motor movements and no cardiovascu-
lar compromise.
Acute respiratory distress with cough and stridor may
occur following minor unintentional aspiration of an oral
vaccine (oral polio or rotavirus vaccine) and may be mis-
taken for anaphylaxis. In very rare instances, an error in
vaccine administration may result in acute collapse and
unresponsiveness that is neither HHE or vasovagal syn-
cope. For example, inadvertent injection of a medication
(for example a muscle relaxant) rather than the vaccine or
following injection of staphylococcal toxin from a contam-
inated vial leading to Toxic Shock Syndrome [34, 35].
The oculo-respiratory syndrome (ORS) is defined by the
onset within 24 h of immunization of at least one of the
following symptoms: bilateral red eyes or respiratory symp-
toms (cough, sore throat, difficulty swallowing, wheeze, dif-
ficulty breathing, chest tightness) or facial edema [36]. The
condition was primarily associated with two Influenza vac-
cines which contained high amounts of aggregated viron
particles that triggered the signs and symptoms that were
not a Type I hypersensitivity reaction [37, 38]. Refinements
in manufacturing resulted in marked reductions in the in-
cidence of this problem. Although ORS symptoms usually
begin several hours after vaccination [37], making the
symptoms less likely to be due to immediate hypersensitiv-
ity, a detailed assessment, including skin testing, may be
required to differentiate ORS from anaphylaxis.
Epidemiology of anaphylaxis
Anaphylaxis following vaccine administration is a rare
event, estimated to occur at a rate of approximately 1 per
million vaccine doses (B) [8]. Fatalities are exceedingly
rare [39] (D). More frequent acute events that occur fol-
lowing administration of vaccines may be confused with
anaphylaxis, including vasovagal reactions, panic (anxiety)
Table 1 Differential diagnosis of anaphylaxis
Anaphylaxis due to other allergenic or external exposures:
Food (including scombroidosis), medication, insect venom,
exercise, heat, cold, idiopathic.
Anaphylaxis due to excess histamine production:
Systemic mastocytosis, mast cell activation syndromes.
Flushing syndromes
Red man syndrome (vancomycin or other medication), carcinoid,
postmenopausal, alcohol-related, vasoactive-peptide tumors
(e.g. pancreatic VIPoma, medullary thyroid carcinoma).
Miscellaneous
Vasovagal episodes, panic attacks, vocal cord dysfunction, C1 inhibitor
deficiency syndromes (hereditary and acquired), pheochromocytoma,
neurologic process (seizure/stroke), cardiovascular process (myocardial
infarction, embolism), capillary leak syndrome, dehydration,
hypoglycemia.
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attacks, and vocal cord dysfunction (Table 1). The correct
diagnosis is critically dependent upon obtaining essential
details in the history surrounding the event [40] (D). This
may provide details of exposure to allergens other than
vaccines, or may discern other possible alternative diagno-
ses (Table 1). An accurate history is also essential to con-
firm that the timing of the event (onset in minutes to 4 h,
see above) is compatible with the biologic plausibility of
anaphylaxis to a vaccine.
Delayed reactions
Rarely, delayed-type hypersensitivity to a vaccine con-
stituent (e.g. aluminum) may cause an injection site nod-
ule, but this is not usually a contraindication to
subsequent vaccination. Delayed anaphylaxis (onset 3 to
6 h after exposure) is a concept that has recently been
well described but in the context of individuals that have
been bitten by the lone star tick and then develop IgE to
a component of red meat, galactose-alpha-1, 3-galactose
(alpha-gal) [41]. One patient with alpha gal allergy has
safely received a gelatin containing vaccine and the au-
thors found no documented published reports of alpha
gal allergy resulting in anaphylaxis following vaccines in
other patients with alpha gal allergy [42]. Of note, the
route of exposure with red meat (ingestion) is different
from the route of administration of vaccines (parenteral)
and a delayed response due possibly to metabolic pro-
cesses is more likely. Thus, vaccine-related allergic reac-
tions including anaphylaxis should occur more quickly
than seen in patients with allergy to red meat. Any
vaccine-related reactions occurring more than 4 h after
administration of a vaccine are unlikely to be immediate
hypersensitivity reactions [43].
Other immunologic reactions
Possible non-IgE-mediated reactions to vaccines include
a broad range of adverse events following immunization
(AEFI) and are commonly listed on the package inserts.
These include mild fever and local reactions to life
threatening infections following live vaccines inappropri-
ately given to patients with immune deficiencies. Known
side-effects from vaccines are detailed on the relevant
Centers for Disease Control (CDC) website [44]. The
Global Vaccine Safety Initiative addressing comprehen-
sive AEFI considerations is reviewed on the WHO
website [45].
Association versus causality
Adverse events that temporally follow immunization are
often attributed to the vaccine, suggesting a causal link
to a component of the vaccine or to the immunologic
response to the vaccine. Many AEFI are coincidental
events that are falsely attributed to vaccines because of
the temporal association. Causality, particularly with rare
events and/or complex multifactorial disorders with
documented delays in diagnosis (e.g. narcolepsy), can be
difficult to prove or disprove. For these reasons, careful
analyses of many AEFIs have failed to substantiate or
rule out a causal association.
Reports of temporal associations do not provide sup-
port for causality, but may indicate a need for future
careful study to collect supportive data for a causal hy-
pothesis [46]. Controlled trials are useful for identifying
an association between administration of a vaccine and
common events that may occur within a relatively short
time period following an immunization, but are not as
helpful for events that occur rarely or are significantly
delayed in onset. In the case of hypersensitivity reac-
tions, especially anaphylaxis, which has an abrupt and
sudden onset usually within minutes following the aller-
genic exposure, a causal relationship is assumed when
there are no other exposures such as food that could
have caused the adverse event. Even when such a tem-
poral association is made, other evidence should be
sought when possible to identify the allergen responsible
and to confirm the absence of evidence that points to an
alternate cause.
The Causality Working Group of the Clinical
Immunization Safety Assessment network have recently
published an algorithm to help guide the systematic evalu-
ation of an AEFI to help determine further steps to care
for specific patients [47] (D) and to provide an assessment
tool to help evaluate causality [48] (D).
In addition, the Institute of Medicine (IOM) engaged
committees of experts to review the epidemiologic, clin-
ical and biological evidence regarding causal associations
with adverse health effects and specific vaccines covered
by the U.S. Vaccine Injury Compensation Program
(VICP). The latest review, titled “Adverse Effects of
Vaccines: Evidence and Causality”, is available online
[49]. The report classifies the evidence regarding many
potential associations between specific vaccines and spe-
cific adverse events as a) convincingly supporting, b) fa-
voring a causal relationship or c) rejecting a causal
relationship. For a large number of other potential asso-
ciations, it was determined “Evidence is inadequate to
accept or reject a causal relationship”.
International efforts to support global standardization
of case definitions for further research on adverse events
are summarized by the Brighton Collaboration and pro-
vide an evolving profile of the questions raised about ad-
verse events possibly linked to vaccines [50]. Further
discussion of the spectrum of AEFI-vaccine questions is
beyond the scope of this review.
Allergic reactions to specific vaccines
In the sections that follow the allergic reactions to several
of the commonly administered vaccines will be reviewed.
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Diphtheria, Tetanus, acellular Pertussis (DTaP) vaccine
Hypersensitivity reactions to diphtheria, tetanus and per-
tussis toxoid containing vaccines are very rare. Most re-
ports concern injection site reactions, and among these
are delayed hypersensitivity to aluminum included in the
vaccine as an adjuvant [51–53] (C for Jackson, D for
Beveridge and for Bergfors). Jackson et al. reported post-
vaccination rates of fever, seizures, medically-attended in-
jection site reactions, and urticaria responses within 7 days
of immunization with DTaP between 1997 and 2000 in a
retrospective population of patients from the Group
Health Cooperative, an health-maintenance organization
based in Seattle, WA with an enrollment of >360,000 per-
sons, including approximately 27,000 children under age
7 years [54] (C). They found an overall rate of 3.9 episodes
of urticaria reported per 10,000 doses of vaccine distrib-
uted. There was a trend toward increased rate of urticarial
reactions with successive administration of the first four
doses, with the highest rate of 8.9 cases per 10,000 for
dose number 4 administered at age 15 months. The rate
then fell to 2.5 for dose number 5, administered at age
5 years. Of the total of 30 visits for rashes diagnosed as
consistent with urticaria, four presented on the day of
vaccination, 11 had onset from days 1 through 3 post-
vaccination, and 15 had onset from days 5 through 7 post-
vaccination. No episodes of anaphylaxis were reported
[54]. Cheng et al. evaluated events suspected or reported
to be anaphylaxis in Australian children (<18 yo) from
2007 to 2013 and estimated a rate of 0.36 cases per
100,000 doses for DTaP [11].
DTP vaccines prior to 1997, but not since, contained
traces of gelatin, either poorly hydrolyzed bovine gelatin
as reported in Japan, or hydrolyzed porcine gelatin.
Some have speculated that this may have resulted in
gelatin sensitization in select populations [55, 56] (D),
but this has not been established as a cause for aller-
gic reactions to DTaP, and others refute this connec-
tion [57] (D).
Influenza vaccine
Influenza vaccines are unique in that the vaccine formu-
lation changes often, based upon the strains of influenza
projected to circulate in the upcoming season. In 2009,
in response to a global influenza pandemic, a monova-
lent vaccine for pandemic influenza (H1N1) was intro-
duced separately from the recommended seasonal
influenza vaccine. Subsequently the H1N1 pandemic
vaccine component has been included as the H1N1
component of the seasonal vaccine. Most influenza vac-
cines marketed currently are produced in embryonated
chicken eggs, and therefore contain small amounts of
egg proteins, most notably ovalbumin, the amounts of
which may vary by vaccine manufacturer and vaccine
lot. A new recombinant influenza vaccine produced in a
baculovirus-insect cell system (Flublok®) is currently li-
censed in the United States only for recipients aged 18–49
years. This vaccine has reduced immunogenicity in chil-
dren when compared with standard egg-grown vaccines
[58] (B). Another recently licensed influenza vaccine is
produced in cell culture (Flucelvax®) [59].
A previous severe allergic reaction to influenza vaccine,
regardless of the component suspected of being respon-
sible for the reaction, requires evaluation before future re-
ceipt of the vaccine in question or an alternative vaccine.
A 2014 publication reviewed the 2011 report of the In-
stitute of Medicine concerning the adverse effects of
childhood vaccines and also updated the findings by
searching the following databases: DARE (Database of
Abstracts of Reviews of Effects), the Cochrane Database
of Systematic Reviews (Cochrane Reviews), Cochrane
Central Register of Controlled Trials (CENTRAL),
PubMed, Excerpta Medica dataBASE (EMBASE), Cumu-
lative Index to Nursing and Allied Health (CINAHL),
Toxicology Literature Online (TOXLINE), Advisory
Committee on Immunization Practices (ACIP) state-
ments, and vaccine package inserts. In this extensive re-
view of adverse events reported following influenza
immunization, anaphylaxis was not commented upon,
due to its infrequent occurrence [60] (D).
An analysis of reports to VAERS of reactions fol-
lowing the 2009 administration of the H1N1 monova-
lent influenza vaccine revealed an overall rate of 10.7
immediate hypersensitivity reactions per million vac-
cine doses distributed, with a 2-fold higher rate for
live attenuated vaccine as compared to inactivated
vaccine [61]. The rate of anaphylaxis was 0.8 per mil-
lion doses, with no significant differences by type of
vaccine or manufacturer. A Vaccine Safety Datalink
study (VSD) covering influenza vaccine immunizations
in the 2012–2013 influenza season failed to find an in-
crease in risk of anaphylaxis related to influenza vaccine
administration compared with historical controls, adjust-
ing for age and site. Among over 3.3 million first doses of
Inactivated Influenza Vaccine (IIV) administered to indi-
viduals age 6 months and older, there were seven cases of
reported anaphylaxis and no cases of anaphylaxis reported
among 232,406 first doses of Live Attenuated Monovalent
Influenza Vaccine (LAMV) administered. This compared
with 18 cases of anaphylaxis per 11.2 million doses IIV
and two cases per 338,000 doses of LAMV in the histor-
ical seasons of 2005–2006 through 2009–2010 [62](C).
Similarly, a review of reported adverse events following
immunization for pandemic monovalent H1N1 vaccine in
Latin American and the Caribbean in the 2009–2010
season reported anaphylaxis as 7.6 % of the 1000 events
supposedly attributable to vaccines and immunizations,
representing a rate of 0.53 cases per million doses (0.41–
0.64, 95 % CI). Of these, 45/76 cases occurred in age
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group 18–59 years, and 14 occurred in those under age
2 years [63] (D).
Egg allergy does not appear to impart an increased risk
of an anaphylactic reaction to immunization with either
inactivated or live attenuated influenza vaccines cur-
rently available in the United States and Europe (dis-
cussed in detail below under the heading "Approach to
the patient with possible allergies to foods or other
materials that may also be components of vaccines or
vaccine packaging"). Although cases of immediate hyper-
sensitivity reaction such as urticaria may occur, they ap-
pear to be no more common in egg-allergic than non-
egg-allergic vaccine recipients [64, 65] (D). A review of
articles in 2008 relating to allergic reactions, asthma, or
food allergy yielded a number of cases of anaphylaxis
following LAIV, although no evidence was found of a
direct causal relationship to egg allergy [66] (D). Egg
proteins are not the only component of influenza vac-
cines that may be responsible for an immediate allergic
reaction.
The preservative, thimerosal, has been rarely impli-
cated as causing allergic reactions to influenza vaccines
but has not clearly demonstrated to be responsible [67]
(D). Latex may be present in the rubber stopper of some
vaccine vials and plungers in some prefilled syringes, but
this appears to be a very rare issue for latex-sensitive in-
dividuals [68] (C). IgE directed toward the influenza
component itself is rarely implicated in hypersensitivity
reactions [4, 43] (D). Other allergic or hypersensitivity
reactions described following immunization with influ-
enza vaccine may not be IgE-mediated [43].
The United States joint task force on Practice Param-
eters of the AAAAI and ACAAI states that “special pre-
cautions regarding medical setting and waiting periods
after administration of IIV to egg-allergic recipients
beyond those recommended for any vaccine are not
warranted." [139] (D). The Canadian National Advisory
Committee on Immunization (NACI) Immunization
Guide Chapter on Influenza and Statement on Seasonal
Influenza Vaccine for 2015–2016 states “regarding ad-
ministration of influenza vaccine to egg allergic per-
sons, after careful review, NACI has concluded that egg
allergic individuals may be vaccinated against influenza
using trivalent influenza vaccine (TIV) without prior
influenza vaccine skin test and with the full dose, irre-
spective of a past severe reaction to egg and without
any particular consideration, including immunization
setting [69].
Measles Mumps and Rubella (MMR) vaccines
Most cases of anaphylaxis associated with MMR vac-
cines have been traced to the content of gelatin, which is
used as a stabilizer. Reports of anaphylaxis following
MMR have been reported for several decades, but the
highest rate occurred prior to 1998, when the vaccines
contained 0.2 % gelatin, with most reports coming from
Japan. Nakayama et al. reported 366 cases of clinical
reactions to MMR, of which 34 were anaphylaxis, 76
urticaria, and 215 cases had non-urticarial generalized
eruption, while 41 had local reactions only. When
serum was available, IgE antibodies to gelatin were de-
tected in 25/27 (93 %) of those with anaphylaxis, 27/48
(56 %) of those with urticaria, 8/90 (9 %) of those with
a generalized eruption, 0/41 with a local reaction only,
and 0/29 control subjects [55] (C). Dramatic decreases
in anaphylaxis/allergic reactions to live measles vac-
cines were observed in Japan immediately after each
manufacturer marketed vaccines that were gelatin-free
or contained a hypoallergenic form of gelatin. Since the
end of 1998 reports of anaphylaxis/allergic reactions to
live measles vaccines had almost disappeared [70, 71].
(D) D’Souza et al. reported adverse events following
immunization to MMR in a review of the Measles Con-
trol Campaign (MCC) conducted in Australia from
August to November 1998. There was only one ana-
phylactic reaction, giving a rate of 0.06 per 100,000
doses administered. The combined rate for anaphylaxis
and allergic reactions was 1.06 per 100,000. The au-
thors concluded that the benefits of the MCC far out-
weighed the risks of serious adverse events associated
with immunization [72] (D).
In a separate report from VAERS, the rate of anaphyl-
actic reactions reported after measles virus-containing
immunization in the United States between 1991 and
1997 was 1.8 per one million doses distributed. Cases of
anaphylaxis reported to VAERS during this time period
were identified retrospectively and 57 subjects were re-
cruited into a follow up study to investigate allergenic
sensitization in relation to the event. Self-reported his-
tory of food allergy was present more frequently in the
interviewed study subjects compared with controls who
had also received vaccine without clinical reaction.
Serum IgE analysis on 22 subjects showed that six
(27 %) tested positive for anti-gelatin IgE, and none of
27 controls tested positive for anti-gelatin IgE. The levels
of IgE antibody against egg and against all three viral an-
tigens did not differ among study subjects and among
controls [57] (D).
Concerns regarding risk of allergic reaction following
MMR immunization of subjects who have clinical allergy
to egg have been laid to rest. The manufacture of vac-
cines containing live virus produced in chick embryo
cultures (measles and mumps) and human diploid cell
culture (rubella) has resulted in a vaccine that contains
no, or at most picogram quantities of egg protein, insuf-
ficient to cause an allergic reaction [73, 74]. In addition
to those reports mentioned above, this has been con-
firmed in Iran [75] (D), Denmark [76] (D), Spain [77]
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(D), Finland [78] (D), and the United States [79, 80] (C
or D). Persons with egg allergy can safely receive measles
vaccine or MMR.
Minor allergic reactions with MMR vaccine are also
infrequent. A prospective review of patients referred to
an emergency department vaccination service in Dublin,
Ireland included all referred cases for immunization
from January 1, 2006 through December 31, 2010. Of
the total 446 vaccines administered during the study
period, 310 (69.5 %) were MMR. The majority of cases
(261/310, 84.2 %) had been referred from the commu-
nity for suspected egg allergy. Only six patients (1.3 %)
experienced an immediate reaction to the vaccine and
all reactions were minor [81] (D).
Varicella vaccine
Varicella vaccines contain an attenuated live strain of
varicella virus (Oka) combined with other components,
including gelatin as a stabilizer. From May 1, 1995
through April 30, 1999, when over 16.1 million doses of
Varivax (Merck) were distributed, a post-marketing
safety study reported a total of seven cases of anaphyl-
axis in children ages 3 to 8 years. All but one occurred
shortly after vaccine administration. Symptoms consisted
of wheezing, stridor, swollen lips, urticaria, hypotension,
coughing and itching. All affected were treated appropri-
ately and recovered. In addition, there were 1349 cases
of post-immunization rashes of which 4 % were classi-
fied as consistent with hypersensitivity [82] (D).
A separate post-licensure study of the VAERS database
from March 17, 1995 through July 25, 1998 revealed 6574
case reports of adverse events after varicella immunization,
a rate of 67.5 reports per 100,000 doses distributed. Ap-
proximately 4 % of reports were categorized as serious,
including 14 deaths. The most frequently reported were
rashes, possible vaccine failures and injection site reac-
tions. There were 30 cases of reported anaphylaxis, none
of which resulted in fatality [83] (D).
Similar to reports from Japan implicating the gelatin
ingredient of MMR vaccine as a potential trigger for
anaphylaxis, Sakaguchi et al. reported that anaphylaxis
following administration of the varicella vaccine was as-
sociated with IgE antibody directed toward the gelatin
component [84] (D). The estimated incidence of severe
anaphylaxis associated with varicella vaccine from 1994
to 1996 in Japan was 10.3 cases per million doses of vac-
cine administered [85] (D). Ozaki et al. reported a rate
of 28 serious anaphylactic reactions and 139 non-serious
allergic reactions following gelatin-containing varicella
vaccine from 1994 to 1999, when 1.41 million doses of
varicella vaccine were distributed in Japan. All nine sera
available from children with anaphylaxis were found to
test positive for anti-gelatin IgE, whereas 55 of the 70
available sera from children with non-serious allergic
reactions were positive. Conversely, there were no cases
of anaphylaxis and only five cases of non-serious allergic
reactions from 1999 to 2000 when 1.3 million doses of
gelatin-free varicella vaccine were distributed [86]. The
authors concluded that the newer vaccine was safe and
also provided data that the immunogenicity was compar-
able to the earlier gelatin-containing vaccine [86] (D).
Japanese encephalitis vaccine (JE-VC)
Vaccination is the single most important measure in pre-
venting this disease. In March 2009, the U.S. Food and
Drug Administration (FDA) licensed an inactivated, Vero
cell culture-derived JE-VC (Ixiaro®) for use in adults.
The vaccine replaced the prior Japanese Encephalitis
Vaccine (JEV) that was derived from mouse brain and
was licensed based on clinical trial safety data in 3558
JE-VC recipients.
A summary of the adverse events reported to VAERS
for adults (≥17 years) who received JE-VC from May
2009 through April 2012 was recently published and in-
cluded data on 275,848 JE-VC doses distributed [87].
Over the 3 year period, 42 adverse events following vac-
cination with JE-VC were reported to VAERS for an
overall reporting rate of 15.2 adverse events per 100,000
doses distributed. Of the 42 total reports, five (12 %)
were classified as serious for a reporting rate of 1.8 per
100,000 doses distributed; there were no deaths. Hyper-
sensitivity reactions (N = 12) were the most commonly
reported type of adverse event, with a rate of 4.4 per
100,000 doses distributed; no cases of anaphylaxis were
reported. Three adverse events of the central nervous
system were reported (one case of encephalitis and two
seizures) for a rate of 1.1 per 100,000; all occurred after
receipt of JE-VC with other vaccines. In conclusion,
these post-marketing surveillance data suggest a good
safety profile for JE-VC consistent with findings from
pre-licensure clinical trials [87].
The newer inactivated Vero cell culture derived JE-VC
vaccine does not contain potential mouse brain antigens
nor gelatin as did the older vaccine, but does contain
some protamine sulfate from the virus preparation step
that requires protamine sulfate treatment to remove
contaminating DNA and proteins. Protamine has been
characterized as an allergen in the context of insulin al-
lergy with protamine specific IgE contributing to the re-
actions [88]. Clinical trials safety data (less than 5000
vaccinees) did not show the serious systemic hypersensi-
tivity reactions described with the older vaccine. Adverse
events consistent with systemic hypersensitivity were ob-
served at similar frequencies in recipients of the new
vaccine (3.5 %) and the placebo (3.7 %) group. The
placebo contained phosphate buffered saline and alum
adjuvant so it was not an “inert” placebo. While stud-
ies to date suggest reduced risk of hypersensitivity
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reactions with the gelatin free newer vaccine, the ac-
tual incidence of potentially IgE-mediated reactions
remains undefined. The package insert includes a cau-
tion in the setting of prior JEV reaction history and a
documented hypersensitivity to protamine. Evaluation
of future vacinees with serious immediate hypersensi-
tivity reactions merit consideration of protamine as a
relevant allergen [89, 90].
Rabies vaccine
From October 1997 through December 2005, the Vac-
cine Adverse Event Reporting System (VAERS) received
336 reports of AEFIs to the purified chick embryo Cell
(PCEC, RabAvert) vaccine, 20 of which were classified as
serious, following vaccination in the U.S. Of the 20 ser-
ious AEFIs, three were classified as possible anaphylaxis.
Most reported AEFIs are non-serious and consistent
with pre-licensure safety data [91].
Reactions to the human diploid rabies vaccines were
also reported from Poland [3]. In 289 patients receiving
rabies diploid vaccine produced by Merieux, postvacci-
nation reactions (14 %) included mainly local reactions
with reddening, edema and pain at the injection site.
These changes were short-lasting and resolved spontan-
eously in most cases. Systemic reactions included mainly
fever with malaise (2 %), headaches and low mood
(1.7 %). These reactions were also short-lasting and left
no sequelae. Allergic reactions of the type of hyperergic
purpura and urticaria were found in only isolated
cases (0.3 %) [92].
Tick-borne Encephalitis (TBE) vaccine
TBE vaccines target members of the virus family Flavi-
viridae that is one of the major human pathogenic flavi-
viruses causing potentially serious neurologic disease via
three subtypes (European, Far Eastern and Siberian).
The disease burden related to this pathogenic virus
group continues to be of great concern [93, 94]. The
TBE vaccine is not licensed in the US but is widely used
in western and central Europe with over 100 million
doses administered between 1980 and 2010 and major
success in preventing TBE viral infections [95]. The
safety surveillance experience has been reassuring. Im-
mediate hypersensitivity reactions and anaphylaxis have
not been reported as a post-marketing safety surveillance
concern. In a PubMed search in April of 2015, only two
publications can be found describing gelatin-induced
urticaria and anaphylaxis (all associated with the older
formulation). For post marketing surveillance of imme-
diate allergic reactions, only one publication in 2004
reported a frequency of two per 100,000 doses with pre-
sumed linkage to the polygeline constituent. The newer
vaccine introduced in 2002 (without polygeline for
pediatric populations) demonstrated “no serious or
unexpected adverse events related to vaccination were
reported … more than 3000 voluntary subjects” [96]. As
discussed above with Japanese encephalitis vaccine,
whether or not protamine may become a clinically im-
portant allergen for susceptible individuals remains to be
seen [97]. Finally, the package insert for the Canadian
licensed vaccine states that "In the large clinical trials
conducted to date, there were no reports in adults or
children of serious clinical events, such as seizures, or of
systemic allergic reactions, considered to be causally re-
lated to the vaccination." [98].
Allergic reactions to vaccine components
Vaccines contain whole organisms or parts of organisms
and/or inactivated toxins (toxoids) that induce protective
immune responses. These vaccine antigens rarely, if ever,
are the cause of hypersensitivity reactions. Recently, the
mutant, non-toxic form of diphtheria toxin (CRM
(197)), used as a carrier protein in Prevnar-13, was
implicated as a cause of anaphylaxis in a 12 month
old infant [99] (D). CRM (197) had previously been
implicated as the allergen in a reaction to a Hib con-
jugate vaccine [100]. Other vaccine components that
can induce allergic responses include residual media
used to grow the organisms (e.g. yeast), adjuvants
(e.g. aluminum salts), stabilizers (e.g. gelatin), antibiotics,
preservatives (e.g. thimerosal) and trace amounts of
latex from vaccine vial stoppers or syringe plungers
in some vaccines (Table 2) [101, 102]. A complete list
of all vaccine components that could be potential al-
lergens can be found at the website of the Institute
Table 2 Recommended approach to patients with possible
allergies to components of vaccines
Component Vaccines Recommendation
Egg MMR Give vaccine in usual manner
without special precautions
Influenza Give vaccine in usual manner
without special precautions
Yellow Fever Skin test with vaccine and if
positive, administer in graded
doses under observation
Gelatin See Table 4 Skin test with vaccine and
if positive, administer in
graded doses under
observation
Milk DTaP Give vaccine without special
precautions
Tdap
Yeast Hepatitis B Skin test with vaccine and if
positive, administer in graded






Give vaccine without specific
precautions
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for Vaccine Safety of the Johns Hopkins University
Bloomberg School of Public Health [103]. Many of
these components are present in small amounts that
are usually insufficient to induce allergic reactions in
most individuals with possible hypersensitivity to the
component. However, individuals with unusually high
levels of IgE antibody can theoretically react to very
small amounts of these antigens and develop severe
reactions, including anaphylaxis.
Residual media
Residual small amounts of media to grow organisms are
often found in both inactivated and live vaccines. For ex-
ample, viruses are grown in cell lines. No intact cells from
these cell lines persist in live or inactivated vaccines, and
purification removes most of the cellular material, but it is
impossible to remove all of the components.
Adjuvants
Adjuvants are used to enhance the immune response to
vaccines. Aluminum hydroxide and aluminum phos-
phate are the most common adjuvants used in vaccines.
No immediate hypersensitivity reactions have been
documented due to these adjuvants. However, contact
allergy and small granulomas or nodules with persistent
urticaria at the site may occur following aluminum con-
taining vaccines and were observed in 38 of 4758
(0.83 %) prospectively followed children [104]. These ur-
ticarial granulomas usually persist for several months
and rarely up to several years. Follow up 5 to 9 years
after initial diagnosis in affected children revealed that
the majority of children were no longer positive to
aluminum contact allergy testing [105]. Larger recurrent
nodules at the sites of injection of aluminum containing
vaccines have been reported rarely and have resulted in
biopsies to rule out tumors in predisposed individuals
[106]. An increased rate of anaphylaxis and other imme-
diate hypersensitivity reactions was reported in Canada
associated with an AS03 (trade name for a squalene-
based immunologic adjuvant used in various vaccine
products by GlaxoSmithKline) adjuvanted pandemic
H1N1 influenza vaccine [107]. A case–control study re-
vealed higher rates of food allergy in affected individuals,
but no evidence that the reactions were due to this adju-
vant has been provided [108]. No increased risk of aller-
gic reactions was noted in a systematic review of the
safety of the MF59 (trade name for a squalene-based im-
munologic adjuvant by Novartis) adjuvanted influenza
vaccine in children used in Europe [109]. This vaccine
has been licensed for use in persons ≥ 65 years of age in
the U.S. and there is no indication of an increase in re-
ports of allergic reactions in clinical trials in the elderly
to date [110].
Antimicrobial agents
Gentamycin, tetracycline, neomycin, streptomycin, and
polymyxin B are used during the production process for
vaccines to prevent growth of bacteria or fungi [103]. Al-
though most of these antimicrobials are removed during
the purification process, trace amounts may be present
in some vaccines. These antimicrobial agents can cause
contact or rarely systemic hypersensitivity reactions
when used in clinical settings at therapeutic doses (e.g.
treatment of an infection). However, allergic reactions
associated with the trace amounts present in vaccines
have not been well documented [111].
Preservatives
Thimerosal and 2-phenoxyethanol are used in multidose
vials of vaccines to prevent bacterial growth. Thimerosal
was used in several vaccines used in the United States
until 2001, but was removed as a preservative in vaccines
used in young infants as a precautionary measure because
of theoretical concerns about mercury toxicity [102].
Some multi-dose vials of inactivated influenza vaccines
contain thimerosal and trace amounts may be found in
some other vaccines where thimerosal was used during
the production process, but most was removed from
the final product. Thimerosal in vaccines has been
associated with contact allergy and rarely with sys-
temic allergic reactions [112, 113]. 2-Phenoxyethanol
and phenol have not been associated with immediate
hypersensitivity reactions.
Latex
Natural latex can cause immediate hypersensitivity re-
actions, including anaphylaxis [114]. Latex is present in
the rubber stoppers on some vaccine vials, and on the
plungers in some prefilled vaccines syringes (see
Table 2). There are reports of immediate hypersensitiv-
ity reactions to latex in this setting, but in most
instances, specific studies have not been done to deter-
mine that latex was the cause of the immediate hyper-
sensitivity reaction [43, 115]. Nevertheless, patients
with severe latex allergy should avoid vaccines packaged
with latex-containing stoppers and syringe plungers if pos-
sible. Alternative vaccines without the risk of exposure
to natural latex may be available. Synthetic latex
which is not allergenic, has replaced natural latex in
most products. A list of vaccines that contain natural
latex in the packaging can be found in the index of
the CDC Pink Book [116].
Approach to the patient with a history of an allergic
reaction to a vaccine
Several excellent practice parameters, reviews, and
guidelines have been published describing the clinical
management of patients with suspected vaccine allergy
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[4, 117–120]. The approach suggested by Caubet and
colleagues [120] is reproduced, with minor modifica-
tions, here in Fig. 1. Caveats that may alter management
for specific patients are mentioned in the legend to Fig. 1
and are discussed in more detail by Wood et al. [119]
and Kelso et al. [4].
Approach to the patient with concerns regarding possible
allergic reactions to vaccines
Some recommendations may change so the reader is en-
couraged to access the most up to date information
whenever possible, such as from the Centers for Disease
Control (www.cdc.gov/vaccines). Investigation of allergic
reactions following the receipt of multiple vaccines sim-
ultaneously and/or combined vaccines is increasingly
common and can be challenging. If serologic or skin
testing are indicated the investigator may choose to
prioritize the evaluations based on what they suspect to
be the most likely allergens. When proceeding to the ad-
ministration of additional doses of indicated vaccines,
the investigator will need to assess each vaccine separ-
ately when possible. Conjugate polysaccharide-protein
vaccines may require investigation of the proteins that
are conjugated to the polysaccharides as well as other
vaccine components as the plain polysaccharides are less
likely causes of allergic reactions.
Most questions about vaccine allergy result from two
general concerns. The first relates to patients who have
had a possible reaction to prior vaccination, while the
second relates to patients with a known allergy – such
as egg allergy – that might put them at risk for specific
immunizations (see below under the heading "Approach
to the patient with possible allergies to foods or other
materials that may also be components of vaccines or
vaccine packaging"). Here we will focus on the patient
presenting with concerns regarding a suspected reaction
to a prior vaccine. The specific approach to these pa-
tients needs to carefully consider several key questions:
1. Was the reported event consistent with an IgE
mediated allergy in terms of signs, symptoms, and
timing? For example, the patient with a history of
urticaria, angioedema, and respiratory distress
occurring five minutes after vaccine administration
is very different from the patient experiencing a
non-specific rash 24 h after the vaccine was given
(See Definitions, above).
2. Has the patient experienced a documented or
suspected anaphylaxis or rash to any prior
vaccines? If so, this might help to focus the
evaluation on specific vaccine constituents that
are common among the vaccines suspected of
causing reactions.
3. Will the patient need additional doses of this
vaccine or other vaccines with common constituents?
Even if the patient will not need additional doses of
the vaccine, an allergic reaction could indicate
hypersensitivity to a vaccine component that might
Fig. 1 Management of patients with suspected hypersensitivity to a vaccine and patients with known allergy to a vaccine component (modified
from Caubet et al. 2014; Printed with permission of Wiley) [120]. *For egg allergic patients, see text (Approach to the patient with possible allergies to
foods or other materials that may also be components of vaccines or vaccine packaging). **For patients with a positive skin test to a vaccine, consider
risk benefit analysis based on serologic evidence of current immunity and level of risk for target disease. See Wood et al. [119]
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be in other vaccines the patient will receive. Thus, a
thorough evaluation is needed even if no further doses
of the suspect vaccine are required.
With these questions in mind, each patient can then be
approached individually using a combination of clinical as-
sessment, laboratory testing, and cautious re-administration
of necessary immunizations.
Clinical assessment
The clinician should first decide if future doses of the
vaccine are truly needed. This assessment needs to con-
sider the risk of re-vaccination against the risk of acquir-
ing the vaccine preventable disease and of acquired
disease severity. Some vaccines may be considered less
important than others based upon the likely risk of ex-
posure and presence of underlying risk factors. Since
many vaccines are given as a series, some individuals
may mount protective responses from the doses already
administered and fewer than the recommended number
of doses may produce lasting immunity. It may therefore
be a reasonable option to measure and monitor IgG ti-
ters to assess the level of protection and the need for fu-
ture doses, recognizing that antibody levels are not a
useful measure of protection for all vaccines and that
immunity might wane over time.
Allergy testing with vaccines and vaccine constituents
If it is determined that additional doses of a vaccine
should be administered, skin testing with the vaccine
and/or vaccine constituents should be performed. This
process may be relatively simple if only a single vaccine
antigen was administered or far more complicated if
multiple vaccines or multivalent vaccines (e.g. MMR)
were given at the same visit, which is certainly the norm
for the typical pediatric encounter.
A number of approaches to vaccine skin testing have
been suggested but current guidelines recommend that
testing be initiated with a prick skin test to the full
strength vaccine, unless the patient has a history of se-
vere anaphylaxis in which case it is appropriate to dilute
the vaccine 1:10 or even 1:100 to initiate prick skin test-
ing [4, 118] (D). If the prick skin test with full-strength
vaccine is negative, an intradermal test with the vaccine
diluted 1:100 should then be performed. All tests need
to be interpreted carefully with appropriate positive and
negative controls, recognizing that falsely positive skin
test results may occur. These may be the result of true
but clinically irrelevant IgE responses or to irritant ef-
fects of the vaccine. A case control study of a child with
a history of anaphylaxis to the 23-valent pneumococcal
vaccine positive skin tests and in vitro IgE tests to the
whole vaccine, included nine controls [121] (C). In one
study irritant reactions were common at concentrations
of 1:10 or undiluted vaccines, especially with influenza,
MMR, and varicella vaccines [122]. At the 1:100 concen-
tration, rates of irritant reactions were far less common
with the most frequent being 5 % for DT and DTaP and
15 % for influenza. It is also important to recognize that
delayed responses (12–24 h) to vaccine skin tests are
common, most likely representing previously established
cell-mediated immunity, or immune complex formation
in patients with high titers of antibody to vaccine com-
ponents [123] (D), and should not raise concern in the
evaluation of IgE-mediated vaccine allergy [122].
If the suspected vaccine contains specific constituents
known to be potentially allergenic, testing should also be
conducted for those components. These primarily in-
clude egg (for reactions to yellow fever or influenza vac-
cines), gelatin (see Table 3 for the gelatin content of
specific vaccines), latex, and yeast. Skin test reagents for
egg and yeast are commercially available. Prick skin test
solutions for gelatin can be prepared by dissolving one
teaspoon of gelatin powder in 5 mL of normal saline.
Skin test extracts for latex are commercially available in
many countries but not in the United States. In addition
to skin testing, in vitro testing for allergen-specific
IgE is available in most commercial laboratories for
egg, gelatin, latex, and yeast. For gelatin, it is import-
ant that assays for both porcine and bovine products
be conducted.
Examples of skin and serologic testing that would be
appropriate in the evaluation of suspected reactions to
specific vaccines are presented in Table 4.
Administration of vaccines to patients with a history of a
suspected prior allergic reaction
If both skin and in vitro testing are negative, especially if
the intradermal skin test to the vaccine is negative, the
chance that the patient has an IgE-mediated allergy to
the vaccine or to any vaccine constituent is very small.
The usual dose of the vaccine can therefore be adminis-
tered with at least a 30 min observation period after
vaccination in a facility where anaphylaxis can be recog-
nized and managed with epinephrine and other support-
ive treatments.
If skin or in vitro testing to the vaccine or a vaccine
component is positive, alternative approaches to vaccin-
ation should be considered. However, if the vaccine is
considered necessary – that is, the benefit of the vaccine
clearly outweighs the potential risk of vaccine adminis-
tration – it is usually possible to safely administer the
vaccine using a graded dose protocol [4]. These deci-
sions should be carefully considered on a case-by-case
basis, recognizing that even administration using a
graded dose protocol still carries a threoretical risk of
anaphylaxis. This should be conducted with informed
consent and only in a setting prepared to treat
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anaphylaxis. As mentioned earlier, an overall approach
to the patient with a suspected allergic vaccine reaction
is presented in the algorithm in Fig. 1.
Approach to the patient with possible allergies
to foods or other materials that may also be
components of vaccines or vaccine packaging
The most common situation that involve allergists being
asked to evaluate patients is one in which a patient has a
suspected allergy to an ingested substance (e.g. egg,
milk, gelatin) or other allergen (e.g. latex) that is also a
constituent of a vaccine. In some circumstances, pre-
existing allergy to a vaccine component has been dem-
onstrated to be the cause of anaphylactic reactions to
vaccines containing the component (e.g. gelatin). How-
ever, allergy to components of vaccines has been sus-
pected or demonstrated to be the cause of allergic
reactions to vaccines only in very rare circumstances.
Recommendations are outlined below.
Eggs
Asking patients whether or not they are allergic to eggs
is an adequate screen for egg allergy [124]. Most patients
who would have a reaction to the ingestion of egg cooked
by standard means, tolerate egg-containing baked goods
without reaction. Such patients would still be considered
egg-allergic for purposes of vaccine risk assessment [124].
Rare patients may be allergic only to heat-labile egg pro-
teins (raw egg) and might not think of themselves as being
egg-allergic [125].
The measles and mumps components of the measles-
mumps-rubella (MMR) vaccine [126], and one type of ra-
bies vaccine [127] are grown in chick embryo fibroblast
cultures. A report of anaphylactic reactions to MMR vac-
cine in two egg-allergic children led to the notion that the
vaccine contains egg protein that could cause reactions in
egg-allergic recipients [128]. The authors stated that an
assay of the vaccine had shown it to contain 1 ng of ov-
albumin [128], although a previous study was unable to
detect ovalbumin [129] and a subsequent study was able
to detect only "37 pg of ovalbumin-like material" [79].
Even if the vaccine contains measurable amounts of
ovalbumin or cross-reacting proteins, these reported
amounts would be too small to elicit allergic reactions
[130]. Numerous studies have demonstrated the safety of
MMR in large numbers of egg-allergic children [80, 131]
Table 3 Gelatin-containing vaccines approved for use in the United States (black type) and Europe (blue type) 2015
Vaccine Gelatin content
Influenza (Fluzone [only in standard dose trivalent IM], Sanofi Pasteur) 250 micrograms per 0.5 ml dose
Influenza (FluMist, MedImmune Vaccines) 2000 micrograms per 0.2 ml dose
Influenza (Fluenz Tetra, MedImmune LLC) Unspecified amounta hydrolyzed gelatin, type A per 0.2 ml dose
Measles, Mumps, Rubella (MMRII, Merck) 14,500 micrograms per 0.5 ml dose
Measles, Mumps, Rubella, Varicella (M-M-RVAXPRO, Sanofi Pasteur) Unspecified amounta hydrolyzed gelatin per 0.5 ml dose
Measles, Mumps, Rubella, Varicella (ProQuad, Merck) 11,000 micrograms per 0.5 ml dose
Measles, Mumps, Rubella, Varicella (ProQuad, marketed in Europe by Sanofi Pasteur) Unspecified amounta hydrolyzed gelatin per 0.5 ml dose
Rabies (RabAvert, Novartis) 12,000 micrograms per 1.0 ml dose
Typhoid Vaccine Live Oral Ty21a (Vivotif, Crucell) Capsule
Varicella (VARIVAX, Merck) 12,500 micrograms per 0.5 ml dose
Yellow Fever (YF-VAX, Sanofi Pasteur) 7,500 micrograms per 0.5 ml dose
Zoster (ZOSTAVAX, Merck) 15,580 micrograms per 0.65 ml dose
Zoster (ZOSTAVAX, marketed in Europe by Sanofi Pasteur) Unspecified amounta hydrolyzed gelatin per 0.65 ml dose
aInformation provided in European Public Assessment Reports (EPAR) Product Characteristics documents do not specify quantities for excipients
Table 4 Examples of testing used to assess specific vaccines suspected of causing allergic reactions
Vaccine Skin testing In vitro IgE testing
DTaP, Td, Tdap DTaP, Td, Tdap,Tetanus toxoid, Gelatin, Milk Gelatin, Milk
Hepatitis B Hepatitis B, Yeast Yeast
Influenza Influenza, Egg, Gelatin Egg, Gelatin
MMR MMR, Measles, Mumps, Rubella, Gelatin Gelatin
Varicella or Zoster Varicella or Zoster, Gelatin Gelatin
Yellow fever Yellow fever, Egg, Gelatin Egg, Gelatin
• Whenever possible, the same vaccine from the same manufacturer that was given at the time of the reaction should be used for testing
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(C). Thus, egg allergy is no longer considered a contra-
indication to the administration of MMR vaccine and re-
cipients need not be screened for egg allergy [7, 132]. As
described below, most anaphylactic reactions to the MMR
vaccine have been attributed to gelatin allergy.
Most injected inactivated influenza vaccines (IIV) and
the intranasally-administered live attenuated influenza
vaccine (LAIV) are grown in eggs and contain measur-
able amounts of ovalbumin [124]. Egg allergy was con-
sidered to be a contraindication to the administration of
these vaccines for many years; however we now know
that these patients can safely receive influenza vaccines
(See previous section "Influenza vaccine") [133]. The in-
cidence of anaphylaxis after influenza vaccine is esti-
mated to be about one per million doses [61, 134, 135].
However, the egg allergy status of the patients who have
had such reactions is unknown and anaphylactic reac-
tions are also reported after administration of egg-free
influenza vaccine [136]. Twenty-eight studies specifically
addressing the safety of the administration of IIV to egg-
allergic recipients have collectively evaluated over 4300
subjects, including over 650 with histories of anaphyl-
actic reactions to the ingestion of egg, with reaction
rates similar to non-egg allergic recipients and without
any serious reactions [130]. This is likely because the
vaccines marketed in the United States do not contain
sufficient ovalbumin to trigger a reaction even in highly
egg-allergic subjects. All influenza vaccines currently
available in the United States and Europe contain less
than 1 mcg of ovalbumin per dose [124, 137, 138]. How-
ever, for many of the vaccines available in other areas of
the world, the egg protein content is unknown.
Given the extensive body of evidence demonstrating
the safety of IIV in egg-allergic recipients, statements
endorsed by the United States Joint Task Force on Prac-
tice Parameters and the Canadian National Advisory
Committee on Immunization have been published
[69, 139]. These documents state that any age approved
influenza vaccine can be used in any patient irrespective
of egg allergy status and that special precautions are not
required [69, 139] (A). As above, anaphylaxis can rarely
occur in any patient after the receipt of any vaccine and
providers should be prepared to recognize and initiate
treatment for such reactions [16].
At the time these recommendations were made, stud-
ies had not addressed the safety of LAIV in egg-allergic
patients. However, three recent studies evaluated the ad-
ministration of LAIV in (collectively) 955 egg-allergic
children with no systemic allergic reactions [140–142]
(Des Roches C; Turner (BMJ) B; Turner (JACI) B). Thus,
LAIV can also be administered safely without special
precautions to egg allergic recipients. In 2015 the ACIP
did not recommend use of LAIV in persons with egg al-
lergy because of a lack of data [143]. For adults with a
history of anaphylaxis following egg ingestion, recombin-
ant IIV was recommended and the guidelines called for
observation for at least 30 min after IIV. These guide-
lines are under active review and should be revised soon
based on the recently completed studies indicating LAIV
can be used in egg allergic individuals and special pre-
cautions may not be needed following IIV.
Yellow fever vaccine is prepared in chicken embryos
[144] and contains measurable amounts of ovalbumin
[129]. The vaccine may also contain chicken proteins
[145]. Anaphylactic reactions have been reported after
receipt of yellow fever vaccine, but the egg allergy status
of these patients is not known [146]. There are no stud-
ies evaluating the administration of yellow fever vaccine
as a single dose in the usual manner to egg-allergic re-
cipients and thus it is unknown whether or not this
would induce allergic reactions. The package insert de-
scribes a protocol for vaccine skin testing in egg-allergic
or chicken-allergic recipients [144]. A prick skin test is
performed with the vaccine diluted 1:10, and if negative,
an intradermal skin test is performed with the vaccine
diluted 1:100. If these skin tests are negative, the vaccine
can be administered in the usual manner. If the skin
tests are positive, the vaccine can be administered in
graded doses under observation giving the following
amounts at 15 min intervals: 0.05 mL of a 1:10 dilution
and then using full strength vaccine, 0.05 mL, 0.10 mL,
0.15 mL and finally 0.20 mL. This or similar protocols
have allowed egg-allergic patients to safely receive yellow
fever vaccine [145, 147, 148].
Gelatin
While simply asking patients if they are allergic to eggs
is typically an adequate screen as above, the same may
not be true for gelatin allergy. Many patients who have
had anaphylactic reactions to gelatin-containing vaccines
tolerate the ingestion of gelatin [149]. Presumably this is
because ingestion allows the digestion of gelatin into
smaller, less allergenic peptide fragments [150]. Thus,
candidates for gelatin-containing vaccines should still be
asked whether or not they are allergic to gelatin, and
those who report such allergy should be evaluated prior
to receiving such vaccines. However, when evaluating a
patient who has suffered an apparent allergic reaction
after receiving a gelatin-containing vaccine, the fact that
the patient can ingest gelatin uneventfully does not ex-
clude gelatin allergy as the cause of the vaccine reaction.
Gelatins used in foods and vaccines may be of bovine
or porcine origin [149], which are extensively, but not
completely, cross-reactive [149, 151, 152]. Serum specific
IgE antibodies for both bovine and porcine gelatin are
commercially available. Although there are no approved
commercial skin test extracts for gelatin, a crude extract
for a prick skin testing can be made by dissolving 1 level
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teaspoon (5 g) of any flavor of sugared gelatin in 5 mL
of normal saline [117]. Consideration should be given to
performing both of the in vitro tests and the in vivo test
in patients with a history of allergic reactions to the in-
gestion of gelatin or the receipt of a gelatin-containing
vaccine [4, 6].
Gelatin is added to many (mostly live attenuated viral)
vaccines as a stabilizer (Table 4). It is the vaccine con-
stituent that has been most convincingly demonstrated
to be responsible for allergic reactions. The original case
report described a patient who suffered an anaphylactic
reaction after receipt of MMR vaccine and who had pre-
viously had allergic reactions after the ingestion of gel-
atin [152]. The only vaccine constituent to which she
made IgE antibody was gelatin and RAST inhibition
studies demonstrated cross-reactivity between food
source gelatin and the pharmaceutical gelatin used in
the vaccine. Subsequent studies demonstrated gelatin to
be the culprit allergen in anaphylactic reactions to MMR
[149, 153, 154], varicella [84, 155], Japanese encephalitis
[156] and TBE vaccines [157]. In some countries, vac-
cine manufacturers have removed gelatin from vaccines
or changed to a more thoroughly hydrolyzed, and thus
less allergenic, gelatin and this has been associated with
marked decreases in allergic reactions to these vaccines
[71, 86, 158, 159].
In a patient with a history of an allergic reaction to the
ingestion of gelatin or to the receipt of a gelatin-
containing vaccine who requires additional doses of the
same or another gelatin-containing vaccine, in vitro and
in vivo gelatin tests should be performed as above. In
addition, a prick skin test should be performed with the
vaccine full-strength and if negative, an intradermal skin
test should be performed with the vaccine diluted 1:100
[4, 119, 122]. If the skin tests are negative, the vaccine
can be given in the usual manner and the patient ob-
served for 30 min afterwards [4]. If the skin tests are
positive and additional doses of the vaccine are required,
the vaccine can be given in incremental doses under ob-
servation, prepared to treat an allergic reaction [4]. For
example, for a vaccine where the volume of the normal
dose is 0.5 mL, the following can be given under obser-
vation at 15 min intervals: 0.05 mL of a 1:10 dilution
and then using full strength vaccine, 0.05 mL, 0.10 mL,
0.15 mL and finally 0.20 mL.
Milk
Milk allergy is quite common, particularly in children. A
case series has been published of eight children with se-
vere milk allergy who had allergic reactions to DTaP or
Tdap vaccines [160]. The children all had very high serum
levels of milk-specific IgE antibody. Skin tests were not
performed with the vaccines. However, although the spe-
cific lots of vaccines that caused the reactions were not
available for testing, other lots of the same vaccines were
assayed and found to contain nanogram quantities of ca-
sein. The bacteria used in preparation of these vaccines
are grown in culture media that contains amino acids de-
rived from casein [160]. A case series has also been pub-
lished of four milk-allergic children who had allergic
reactions after receiving a particular brand of oral polio
vaccine containing alpha-lactalbumin [161]. The over-
whelming majority of milk-allergic children receive these
vaccines uneventfully. If milk allergy is responsible for
these reactions, it likely involves the very rare coincidence
of an exquisitely allergic patient and a particular lot of
vaccine contaminated with larger milk peptide fragments
[162]. Thus, no special precautions are required when ad-
ministering vaccines to milk-allergic patients [162, 163].
However, should a milk allergic patient suffer an allergic
reaction to one of these vaccines, the possibility of milk
protein contaminating the vaccine should be considered.
Yeast
The yeast Saccharomyces cerevisiae is commonly known
as baker's yeast or brewer’s yeast. An occupational dis-
ease known as baker's asthma is usually due to allergy to
cereal grains, [164, 165] but can very rarely be caused by
allergy to S. cerevisiae [166]. This yeast is also a very rare
cause of food allergy [167]. In addition, some patients
believe they suffer from "yeast hypersensitivity syn-
drome", an ill-defined and unproven condition [168],
and might also consider themselves allergic to yeast.
Hepatitis B vaccines may contain viral proteins grown in
S. cerevisiae and contain 1–5 % residual yeast protein
(up to 25 mg per dose) [169, 170]. Quadrivalent human
papillomavirus vaccine also contains residual yeast pro-
tein (less than 7 micrograms per dose) [171]. A review
of 180,895 adverse event reports to VAERS, revealed 107
reports that mentioned a history of allergy to yeast and
occurrence of symptoms after any vaccination [172].
Eighty-two of those 107 reports involved hepatitis B vac-
cine and 11 of those 82 described possible anaphylactic
reactions. The other reports described common vaccine
reactions such as injection site reactions or fever. Four
reports described possible anaphylactic reactions in re-
cipients reporting yeast allergy after receiving non-yeast-
containing vaccines. Thus, both yeast allergy and adverse
vaccine reactions attributable to yeast allergy appear to
be exceedingly rare. A patient who reports yeast allergy
should be carefully questioned about the nature of ex-
posure and nature and timing of symptoms and undergo
prick skin testing or serum specific IgE antibody testing
with S. cerevisiae to reveal the rare patient who may
have symptoms due to IgE-mediated yeast allergy. In
such patients, it would seem prudent, prior to hepatitis
B vaccination, to perform vaccine skin testing and, if
positive, vaccine administration in graded doses as
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described above for gelatin containing vaccines or use a
vaccine not grown in yeast.
Latex
Potential exposure to latex in vaccines is related to the
packaging, either the vial or syringe [173]. The "rubber"
in vaccine vial stoppers or syringe plunger tips may be
dry natural rubber (DNR) latex or synthetic rubber.
Those made with DNR pose a theoretical risk to latex-
allergic patients. However, unlike flexible latex products
such as gloves and balloons from which latex allergen
can be easily eluted [174], it is difficult to elute latex
allergen from these molded rubber products [175]. A re-
view of 167,233 adverse event reports to VAERS revealed
147 reports that mentioned a history of allergy to latex
and occurrence of symptoms after any vaccination [115].
Twenty-eight of these 147 reports described possible al-
lergic reactions in vaccine recipients, only two of whom
were hospitalized and all recovered completely. The re-
ports involved a wide variety of vaccines that may or
may not have contained latex in the packaging. Thus, it
appears that allergic reactions to vaccines caused by
latex in the packaging are exceedingly rare. Therefore,
no special precautions, aside from using non-latex gloves
for the injection, are required when administering vac-
cines to latex allergic patients beyond the brief observa-
tion period recommended after the administration of
any vaccine to any patient. However, as for any patient,
providers should be prepared to treat unusual allergic
conditions and reactions.
Unmet needs
Allergic reactions to vaccines are infrequent but poten-
tially life-threatening events that are poorly understood.
For example, it may be possible to identify risk factors
such as clinical history (e.g. concomitant illnesses), gen-
der, specific genetic polymorphisms, and concomitant
exposures that may work independently or in concert to
increase risk of a reaction or a poor outcome if such a
reaction takes place. In addition, the current evaluation
of patients who have had a severe allergic reaction to a
vaccine is quite cumbersome and would be expedited if
dependable in vitro testing were available. A list of
suggested future studies is presented in Table 5.
Executive summary
Allergic reactions to vaccines are rare events and need
to be distinguished from a variety of less important and
more frequent adverse events following immunization.
Given the large numbers of vaccines given worldwide,
an international consensus for the evaluation and man-
agement of allergic reactions to vaccines as presented
here is important. This document provides comprehen-
sive and internationally accepted guidelines and access
to on-line documents to help practitioners around the
world identify allergic reactions following immunization.
It also provides a framework for the evaluation and fur-
ther management of patients who present either follow-
ing an allergic reaction to a vaccine or with a history of
allergy to a component of vaccines.
Global implications for press releases
Allergic reactions to vaccines are rare occurrences but can
be life threatening. Given the large numbers of vaccines
given throughout the world, it is critical to reach an inter-
national consensus regarding the approach to patients
with possible allergic reactions to vaccines and to patients
with other allergic diseases who may have concerns about
receiving specific vaccines. This International Consensus
Document on “Allergic Reactions to Vaccines” achieves
this goal.
Endnotes
1All relevant references are stratified as having a level
of evidence A-D (see Box 3 in [176]).
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